Phase 4
Completed N=41
Sequencing Treatments for Mothers With ADHD and Their At - Risk Children
Source: ClinicalTrials.gov NCT01816074 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
May 2018
Primary outcomePrimary: Child Behavioral Functioning — 4.78; 4.56; 4.44; 4.67 units on a scale
◆ Published Evidence
Emerging
9citations · ~2 / year
Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.
Summary
We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child. We believe that multi-component interventions combining maternal stimulant medication, Lisdexamfetamine (LDX), and Behavioral Parent Training (BPT) will improve parenting, maternal, and child outcomes. In terms of improved parenting, we hypothesize that some mothers may respond well to LDX or BPT alone and therefore may not require multi-modal treatment, whereas others may benefit most from multi-modal treatment
Linked Publications (2)
-
Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.
-
Sequencing Stimulant Medication and Behavioral Parent Training in Multiplex ADHD Families: A Pilot SMART.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Child Behavioral Functioning |
4.78; 4.56; 4.44; 4.67; 4.33; 3.75 | — |
| SECONDARY Maternal Behavioral Functioning |
4.64; 4.50; 4.82; 4.45; 3.55; 3.67 | — |
Eligibility Criteria
Mothers Inclusion Criteria:
- Sign informed consent
- Be between 21-50 years old (inclusive) at the screening visit and English-speaking
- At screening (after washout, if required) meet full Diagnostic and Statistical Manual (DSM-IV) criteria for ADHD, any subtype
- Have current CGI-S-ADHD rating > 4 and 60), no prior treatment with effective doses of stimulants, defined as one or more weeks of treatment with adequate doses.
Data sourced from ClinicalTrials.gov (NCT01816074) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.